Antibiotic (N*) | (% range) | Mean resistance (n/N*) | (%) | References |
---|---|---|---|---|
Resistance rates in S. aureus isolates from human colonization | ||||
Penicillin(420) | (96–100) | (416/420) | (99%) | Joachim et al. (2018), Geofrey et al. (2015), Joachim et al. (2017), Moremi et al. (2019) |
Ampicillin (151) | (84–100) | (133/151) | (88%) | Katakweba et al. (2016), Okamo et al. (2016), Ngocho et al. (2015) |
Tetracycline (381) | (9–95) | (103/381) | (27%) | Geofrey et al. (2015), Moyo et al. (2014), Katakweba et al. (2016), Okamo et al. (2016), Moremi et al. (2019) |
Erythromycin (402) | (19–100) | (163/402) | (41%) | Joachim et al. (2018), Geofrey et al. (2015), Okamo et al. (2016), Moremi et al. (2019) |
Gentamicin (540) | (9–34) | (105/540) | (21%) | Joachim et al. (2018), Joachim et al. (2017), Moyo et al. (2014), Katakweba et al. (2016), Moremi et al. (2019), Ngocho et al. (2015) |
Co-trimoxazole (443) | (14–66) | (205/443) | (46%) | Joachim et al. (2018), Geofrey et al. (2015), Moyo et al. (2014), Katakweba et al. (2016), Moremi et al. (2019) |
Ciprofloxacin (233) | (4–11) | (15/233) | (6%) | |
Clindamycin (336) | (9–76) | (33/336) | (9.8%) | Joachim et al. (2018), Geofrey et al. (2015), Moremi et al. (2019) |
Cefoxitin (546) | (2–100) | (103/546) | (19%) | Joachim et al. (2018, Geofrey et al. (2015), Moyo et al. (2014), Okamo et al. (2016), Moremi et al. (2019) |
Resistance rates in S. aureus isolates from invasive (blood-borne) infections | ||||
Penicillin (46) | (23–80) | (40/46) | (87%) | Kayange et al. (2010), Onken et al. (2015), Thriemer et al. (2012) |
Ampicillin (50) | (85–100) | (46/50) | (92%) | |
Erythromycin (60) | (20–66) | (38/60) | (63%) | Kayange et al. (2010), Seni et al. (2019a, Thriemer et al. (2012) |
Gentamicin (50) | (26–56) | (21/50) | (42%) | |
Co-trimoxazole (69) | (22–96) | (46/69) | (66%) | Kayange et al. (2010), Seni et al. (2019a), Onken et al. (2015), Thriemer et al. (2012) |
Clindamycin (32) | (44) | (14/32) | (44%) | Kayange et al. (2010) |
Methicillin (245) | (23) | (57/245) | (23%) | Moyo et al. (2010) |
Cefoxitin (69) | (0–32) | (17/69) | (25%) | Kayange et al. (2010; Seni et al. (2019a), Onken et al. (2015), Thriemer et al. (2012) |
Resistance rates in S. aureus isolates from non-invasive infections | ||||
Penicillin (202) | (30–100) | (183/202) | (91%) | Manyahi et al. (2014), Kazimoto et al. (2018), Moremi et al. (2014), Marwa et al. (2015), Moremi et al. (2012) |
Ampicillin (263) | (47–88) | (177/263) | (67%) | |
Tetracycline (67) | (6–45) | (14/67) | (21%) | Marwa et al. (2015), Mushi et al. (2016), Moremi et al. (2012) |
Erythromycin (221) | (14–46) | (81/221) | (37%) | Moremi et al. (2014), Marwa et al. (2015), Mushi et al. (2016), Moremi et al. (2012) |
Gentamicin (339) | (11–52) | (110/339) | (32%) | Mhada et al. (2012), Mwambete and Eulambius (2018), Moremi et al. (2014), Mushi et al. (2016), Moremi et al. (2012) |
Co-trimoxazole (232) | (43–74) | (115/232) | (50%) | Mwambete and Eulambius (2018), Moremi et al. (2014), Marwa et al. (2015), Mushi et al. (2016) Seni et al. (2019b), Moremi et al. (2012) |
Ciprofloxacin (187) | (4–25) | (20/187) | (17%) | Mwambete and Eulambius (2018), Marwa et al. (2015), Mushi et al. (2016) |
Clindamycin (42) | (21–63) | (19 /42) | (45%) | |
Cefoxitin (226) | (1–100) | (55/226) | (24%) | Manyahi et al. (2014), Kazimoto et al. (2018), Moremi et al. (2014), Mushi et al. (2016), Moremi et al. (2012) |